Strata Skin Sciences (Strata Skin Sciences) Risk Assessment

View and export this data going back to 2005. Start your Free Trial

What is Strata Skin Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Strata Skin Sciences is: High Risk: High uncertainty.

Competitive Comparison of Strata Skin Sciences's Risk Assessment

For the Medical Devices subindustry, Strata Skin Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Skin Sciences's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Risk Assessment falls into.

Strata Skin Sciences (NAS:SSKN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Strata Skin Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Strata Skin Sciences (Strata Skin Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

E2OM:Germany E2OM:Germany

Address

5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website

https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

Executives

Shmuel Gov	officer: SVP & General Manager Carlsbad	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein	director	5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc.	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp	10 percent owner	590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz	officer: Chief Financial Officer	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia	director, officer: Chief Executive Officer	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker	director	5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang	director	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727